A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

ConditionProstatic Neoplasms, Castration-Resistant

Trial statusRecruiting

Trial phaseNot listed

Trial typeObservational

Biological sexMale

Age18-115

SponsorNovartis Pharmaceuticals

About this trial

The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.

Eligibility criteria

Qualifiers

Diagnosis of mCRPC between 01 January 2021 and 31 December 2025.

Male sex at index, where index is the date of initial mCRPC diagnosis.

Age 18 years at index.

Disqualifiers

None

Trial design

Treatments tested in this trial

Not listed

Trial groups

17,111 Participants

are grouped into 1 trial group

Sponsors and collaborators

Novartis Pharmaceuticals

Lead sponsor

Source ClinicalTrials.gov